Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
4 competitors in Kidney Transplantation
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Simulect
Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
View on EMALocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Gastric Adenocarcinoma
Metastatic Urothelial Cancer
Clostridium Difficile-associated Diarrhea (CDAD)
Urothelial Cancer